Compare ODD & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ODD | CMPX |
|---|---|---|
| Founded | 2018 | 2014 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 688.4M | 927.5M |
| IPO Year | 2022 | 2020 |
| Metric | ODD | CMPX |
|---|---|---|
| Price | $12.39 | $2.06 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 9 |
| Target Price | ★ $41.00 | $14.57 |
| AVG Volume (30 Days) | 1.3M | ★ 12.1M |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $22.92 | $934.41 |
| P/E Ratio | $16.73 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.80 | $1.61 |
| 52 Week High | $79.18 | $6.88 |
| Indicator | ODD | CMPX |
|---|---|---|
| Relative Strength Index (RSI) | 35.09 | 34.36 |
| Support Level | $10.80 | $1.61 |
| Resistance Level | $16.04 | $3.54 |
| Average True Range (ATR) | 0.87 | 0.14 |
| MACD | -0.13 | 0.13 |
| Stochastic Oscillator | 15.87 | 78.75 |
ODDITY Tech Ltd offers a consumer tech platform that is built to transform the beauty and wellness market. The ODDITY platform is designed to support a portfolio of brands and services that innovate and disrupt the expansive beauty and wellness market. It consumes user data to develop physical beauty and wellness products that deliver performance and functionality. Its brands include SpoiledChild and IL Makiage. Geographically, the company generates majority revenue from United states followed by other countries and Israel.
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.